乙肝病毒B基因型和干扰素α受体β亚基的高表达与中国慢性乙肝感染患者对聚乙二醇化干扰素α-2a的更好反应相关。
Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor β Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection.
作者信息
Fan He Bin, Guo Ya Bin, Zhu You Fu, Chen An Shen, Zhou Mu Xiu, Li Zhi, Xu Li Tong, Ma Xiao Ju, Yan Fu Ming
机构信息
Department of Infectious Disease, The People's Liberation Army 161 Hospital, Wuhan, China.
出版信息
Hepat Mon. 2012 May;12(5):333-8. doi: 10.5812/hepatmon.6173. Epub 2012 May 30.
BACKGROUND
Hepatitis B virus (HBV) is one of leading causes of various hepatic diseases including acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hundreds of million people worldwide are infected by HBV, chronically.
OBJECTIVES
This study in conducted to investigate the influence of Hepatitis B virus (HBV) genotypes and type I IFN-αreceptor β subunit (IFNAR2) expression in liver on response to treatment with pegylated IFN-α-2a (Peg-IFN-α-2a) for chronic hepatitis B infection.
PATIENTS AND METHODS
In this study, 65 eligible patients with chronic hepatitis B disease were enrolled. HBV genotypes of these patients were analyzed by using PCR-RFLP of the surface gene of HBV. The expression of IFNAR2 in the liver was immune histochemically investigated using anti-IFNAR2 antibody. All immune histochemical slides were read semi-quantitatively by image analysis. Chronic hepatitis B patients were treated with Peg-IFN-α2a therapy for a 48-week period and followed up for 24 weeks. Baseline characteristics and sustained viral response (SVR) to Peg-IFN-α-2a therapy were evaluated.
RESULTS
55 % of patients exhibited HBV genotype B and 31.7 % patients exhibited HBV genotypes C infections. After treatment with Peg-IFN-α-2a, SVR was achieved in 66.7 % of patients with HBV genotype B and in 26.3 % of patients with HBV genotype C (P = 0.009). Semiquantitative and the image analysis indicated by gray level values revealed a higher IFNAR2 expression in the group with severe inflammation (P < 0.001). Patients' high IFNAR2 protein expression had a significant impact on SVR to Peg-IFN-α-2a therapy (P = 0.028).
CONCLUSIONS
HBV genotype B and high expression of IFNAR2 in the liver of chronic hepatitis B patients are closely associated with better response to Peg-IFN-α-2a therapy in chronic hepatitis B disease.
背景
乙型肝炎病毒（HBV）是包括急慢性肝炎、肝硬化和肝细胞癌在内的各种肝脏疾病的主要病因之一。全球数亿人长期感染HBV。
目的
本研究旨在探讨乙型肝炎病毒（HBV）基因型及肝脏中I型干扰素α受体β亚基（IFNAR2）表达对聚乙二醇化干扰素α-2a（Peg-IFN-α-2a）治疗慢性乙型肝炎感染疗效的影响。
患者和方法
本研究纳入了65例符合条件的慢性乙型肝炎患者。采用HBV表面基因的PCR-RFLP分析法对这些患者的HBV基因型进行分析。使用抗IFNAR2抗体通过免疫组织化学方法研究肝脏中IFNAR2的表达。所有免疫组织化学切片通过图像分析进行半定量读取。慢性乙型肝炎患者接受Peg-IFN-α2a治疗48周，并随访24周。评估基线特征和对Peg-IFN-α-2a治疗的持续病毒学应答（SVR）。
结果
55%的患者表现为HBV基因型B感染，31.7%的患者表现为HBV基因型C感染。接受Peg-IFN-α-2a治疗后，HBV基因型B患者的SVR率为66.7%，HBV基因型C患者的SVR率为26.3%（P = 0.009）。通过灰度值进行的半定量和图像分析表明，重度炎症组的IFNAR2表达较高（P < 0.001）。患者的高IFNAR2蛋白表达对Peg-IFN-α-2a治疗的SVR有显著影响（P = 0.028）。
结论
慢性乙型肝炎患者肝脏中的HBV基因型B和IFNAR2高表达与慢性乙型肝炎疾病对Peg-IFN-α-2a治疗的较好应答密切相关。
Zotero 插件